Gender, age, marital status, previous obesity history, education level, accompanying illnesses like diabetes, hypertension, dyslipidemia, atherosclerotic heart disease, hypothyroidism, medications and smoking are known to be the risk factors of obesity.1,2 In our previous study conducted in 2005, sedentary life style and dyslipidemia in males, being unemployed, having lower level of education and having hypertension in females and familial obesity in both genders were found to be related to increased obesity risk.10 In our present study, age, gender, marital status, previous obesity history, hypertension, dyslipidemia, smoking, hypothyroidism and antidiabetic drug
usage in diabetics were found to be significant risk factors for obesity development.
Prior to enrolment, participants were inadequately controlled on one oral antidiabetic drug
However, a handful of previously conducted studies provide data on the glycemic control by the individual antidiabetic drug
class based on fasting plasma glucose and postprandial blood glucose for a short duration, i.e., 3 or 6 weeks.
DPP-4 inhibitors are an antidiabetic drug
class on which there is abundant clinical experience, since they have been marketed for over a decade (since 2006).
Bromocriptine mesylate denotes a novel antidiabetic drug
in view of its unique action on hypothalamic centers.
Although the percentage reduction was the highest in group A (47.37%) as opposed to group E (33.70%), however, it still indicates a potential antihyperglycemic action of CMEDT which maybe similar to the standard antidiabetic drug
Park et al., "Trends of antidiabetic drug
use in adult type 2 diabetes in Korea in 2002-2013: nationwide population-based cohort study," Medicine, vol.
Metformin has been used extensively as a first-line therapy for Type 2 diabetes (T2DM)  and is the most prescribed antidiabetic drug
in the US.
The frequency for users of mono antidiabetic drug
was 130 (65%) patients; and for combination antidiabetic drug
was 70 (35%) patients.
The sodium-glucose cotransporter-2 inhibitors are the newest of these three antidiabetic drug
The antidiabetic drug
was not at all indicated for this non-diabetic patient but wrongly dispensed by the pharmacist/chemist instead of calcium tablet which was one of the regular medications of the patient
Sander et al., "Clinical and economic outcomes of appropriate oral antidiabetic drug
(OAD) treatment among type 2 diabetes mellitus (T2DM) patients with chronic kidney disease (CKD)," in Proceedings of the 71th Scientific Sessions of American Diabetes Association, pp.